Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EHang Holdings Ltd - ADR (EH) vs Viatris Inc (VTRS) Price & Performance

EHang Holdings Ltd - ADRTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

EHang Holdings Ltd - ADR vs Viatris Inc — how do they compare? EHang Holdings Ltd - ADR trades at $4.12 (market cap $309.45M), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 64.7× EHang Holdings Ltd - ADR's market cap, and Viatris Inc pays a 2.75% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and Viatris Inc for 57 Days on average.

EHVTRS
Market Cap
$309.45M$20.03B
Volume
765,79914,109,977
Sector
IndustrialsHealth
52-Week High
$18.94$18.27
52-Week Low
$4.03$9.74
Typical Hold Time
46 Days57 Days
Enterprise Value
$261.14M$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EHang Holdings Ltd - ADR

EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $275.98 million on $417.98 million revenue in 2025, with negative profit margins and ROE. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a volatile backdrop.

The outlook remains challenging due to persistent losses and regulatory scrutiny, though the company's cash position of $1.12 billion provides some buffer. Investment opportunities hinge on successful commercialization of eVTOL technology, while risks include execution missteps, intense competition, and ongoing legal probes. The stock is suitable only for high-risk investors betting on long-term AAM adoption.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EH
100% Buy0% Sell
Avg holding period · 46 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →